Literature DB >> 18476036

Epidemiology and clinical outcome of patients hospitalized with pelvic inflammatory disease complicated by tubo-ovarian abscess.

Y Chan1, W Parchment, J H Skurnick, L Goldsmith, J J Apuzzio.   

Abstract

OBJECTIVE: The purpose of this retrospective study was to compare the clinical outcome and characteristics of pelvic inflammatory disease (PID) complicated by tubo-ovarian abscess (TOA) with PID without TOA.
METHODS: Chart reviews were performed for all PID admissions to the University of Medicine and Dentistry of New Jersey-University Hospital, Newark, NJ, from January 1, 1992, to December 31, 1993.
RESULTS: The incidence in this study of TOA based on sonographic evidence of a complex adnexal mass was 18%. The major differences between the patients with and without TOAs were 1) history of hospitalization for PID: 68% (13/19) vs. 29% (25/85); 2) increased erythrocyte sedimentation rate: 82 vs. 41 mm/h; 3) increased WBC count on admission: 16,200 vs. 14,700/ml; 4) failure to respond to initial antibiotic therapy; and 5) longer hospital stay: 7.8 vs. 4.4 days, respectively. Surgical intervention was required in 3 patients: 2 patients who had TOAs and 1 patient who did not have a TOA by clinical examination or by ultrasound.
CONCLUSIONS: Despite longer hospital stays and blood tests suggesting more severe disease processes, PID complicated by TOA is usually responsive to intravenous (IV) antibiotic therapy without the need for surgical intervention.

Entities:  

Year:  1995        PMID: 18476036      PMCID: PMC2364435          DOI: 10.1155/S1064744995000470

Source DB:  PubMed          Journal:  Infect Dis Obstet Gynecol        ISSN: 1064-7449


  12 in total

1.  Seroprevalence and epidemiologic correlates of human immunodeficiency virus infection in women with acute pelvic inflammatory disease.

Authors:  S Safrin; B J Dattel; L Hauer; R L Sweet
Journal:  Obstet Gynecol       Date:  1990-04       Impact factor: 7.661

2.  Management of the pelvic abscess.

Authors:  E W Franklin; J E Hevron; J D Thompson
Journal:  Clin Obstet Gynecol       Date:  1973-06       Impact factor: 2.190

3.  Sexually transmitted diseases and human immunodeficiency virus infection among women with pelvic inflammatory disease.

Authors:  B Hoegsberg; O Abulafia; A Sedlis; J Feldman; D DesJalais; S Landesman; H Minkoff
Journal:  Am J Obstet Gynecol       Date:  1990-10       Impact factor: 8.661

4.  Criteria for diagnosis and grading of salpingitis.

Authors:  W D Hager; D A Eschenbach; M R Spence; R L Sweet
Journal:  Obstet Gynecol       Date:  1983-01       Impact factor: 7.661

5.  Growth and effect of Neisseria gonorrhoeae in organ cultures.

Authors:  F E Carney; D Taylor-Robinson
Journal:  Br J Vener Dis       Date:  1973-10

6.  Medical and surgical management of the pelvic abscess.

Authors:  B B Benigno
Journal:  Clin Obstet Gynecol       Date:  1981-12       Impact factor: 2.190

7.  Aggressive management of pelvic abscess.

Authors:  A L Kaplan; W M Jacobs; J B Ehresman
Journal:  Am J Obstet Gynecol       Date:  1967-06-15       Impact factor: 8.661

8.  Tubo-ovarian abscess: contemporary approach to management.

Authors:  D V Landers; R L Sweet
Journal:  Rev Infect Dis       Date:  1983 Sep-Oct

9.  Cost of and payment source for pelvic inflammatory disease. Trends and projections, 1983 through 2000.

Authors:  A E Washington; P Katz
Journal:  JAMA       Date:  1991-11-13       Impact factor: 56.272

10.  Current trends in the diagnosis and treatment of tuboovarian abscess.

Authors:  D V Landers; R L Sweet
Journal:  Am J Obstet Gynecol       Date:  1985-04-15       Impact factor: 8.661

View more
  2 in total

1.  Tuboovarian Abscess due to Colonic Diverticulitis in a Virgin Patient with Morbid Obesity: A Case Report.

Authors:  Zafer Selçuk Tuncer; Gokhan Boyraz; Senem Özge Yücel; Ilker Selçuk; Aslıhan Yazicioğlu
Journal:  Case Rep Med       Date:  2012-08-16

2.  Pneumoperitoneum secondary to tubo-ovarian abscess: A case report.

Authors:  Remya Aryad; Sujana Molakatalla
Journal:  Case Rep Womens Health       Date:  2020-02-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.